{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:02:03Z","timestamp":1778763723192,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Farma","award":["Progetto osservazionale sulla psoriasi - SOPso"],"award-info":[{"award-number":["Progetto osservazionale sulla psoriasi - SOPso"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s40261-017-0591-3","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T07:34:08Z","timestamp":1509003248000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy"],"prefix":"10.1007","volume":"38","author":[{"given":"Simona","family":"Lucchesi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Marcian\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Panagia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Intelisano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Randazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Sgroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Altavilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariacarmela","family":"Santarpia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tindara","family":"Franchina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ferra\u00f9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolina","family":"Reitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"591_CR1","unstructured":"European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2009\/12\/WC500020062.pdf. Accessed 4 Aug 2016."},{"key":"591_CR2","unstructured":"Italian Medicines Agency. Position Paper sui Farmaci Biosimilari. 2013. http:\/\/www.agenziafarmaco.gov.it\/sites\/default\/files\/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI.pdf. Accessed 4 Aug 2016."},{"issue":"May","key":"591_CR3","first-page":"11","volume":"12","author":"JP Mach","year":"2012","unstructured":"Mach JP. Introduction to monoclonal antibodies. Cancer Immun. 2012;12(May):11.","journal-title":"Cancer Immun."},{"issue":"15s","key":"591_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/fon-2017-0153","volume":"13","author":"C Buske","year":"2017","unstructured":"Buske C, Ogura M, Kwon H-C, Yoon SW. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements. Future Oncol. 2017;13(15s):5\u201316.","journal-title":"Future Oncol."},{"key":"591_CR5","unstructured":"GABI Journal. Biosimilars applications under review by EMA\u2014April 2017. 2017. http:\/\/www.gabionline.net\/Biosimilars\/General\/Biosimilars-applications-under-review-by-EMA-April-2017?utm_source=Cos2+List&utm_campaign=c62ac00636-GONL+V17E19+AC-c2&utm_medium=email&utm_term=0_b64865923a-c62ac00636-114659593. Accessed 5 Oct 2017."},{"issue":"1","key":"591_CR6","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/S1470-2045(15)00381-2","volume":"17","author":"MJ Renwick","year":"2016","unstructured":"Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17(1):e31\u20138.","journal-title":"Lancet Oncol."},{"issue":"158","key":"591_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","volume":"22","author":"EB Wilson","year":"1927","unstructured":"Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22(158):209\u201312.","journal-title":"J Am Stat Assoc."},{"key":"591_CR8","unstructured":"Ministry of Health. Italian Medicines Agency. Circolare AIFA del 3 agosto 2007. Linee guida per la classificazione e conduzione degli studi osservazionali sui farmaci. http:\/\/xoomer.virgilio.it\/pgiuff\/osservazionali.pdf. Accessed 6 Mar 2017."},{"key":"591_CR9","unstructured":"Italian Medicines Agency. L\u2019uso dei farmaci in Italia\u2014Rapporto OsMed 2015. http:\/\/www.agenziafarmaco.gov.it\/sites\/default\/files\/Rapporto_OsMed_2015__AIFA.pdf. Accessed Aug 2016."},{"key":"591_CR10","unstructured":"Food and Drug Administration. FDA approves first biosimilar for the treatment of cancer. 2017. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm576112.htm. Accessed 2 Oct 2017."},{"key":"591_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ctrv.2016.04.003","volume":"46","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Linton KM, Cervi P, Rosenberg JA, Jacobs I. A clinician\u2019s guide to biosimilars in oncology. Cancer Treat Rev. 2016;46:73\u20139.","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"591_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/00063030-200721060-00003","volume":"21","author":"AA Genazzani","year":"2007","unstructured":"Genazzani AA, Biggio G, Caputi AP, Del Tacca M, Drago F, Fantozzi R, et al. Biosimilar drugs: concerns and opportunities. BioDrugs. 2007;21(6):351\u20136.","journal-title":"BioDrugs."},{"issue":"2","key":"591_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5639\/gabij.2015.0402.018","volume":"4","author":"A Mack","year":"2015","unstructured":"Mack A. Norway, biosimilars in different funding systems. What works? GABI J. 2015;4(2):90\u20132.","journal-title":"GABI J"},{"key":"591_CR14","unstructured":"GaBI Online\u2014generics and biosimilars initiative. Biologicals patent expiries. 2015. http:\/\/www.gabionline.net\/Biosimilars\/General\/Biologicals-patent-expiries. Accessed 5 Oct 2017."},{"issue":"4","key":"591_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-015-0132-7","volume":"29","author":"Y Ingrasciotta","year":"2015","unstructured":"Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, et al. How much are biosimilars used in clinical practice? A retrospective Italian population-based study of erythropoiesis-stimulating agents in the years 2009-2013. BioDrugs. 2015;29(4):275\u201384.","journal-title":"BioDrugs."},{"issue":"4","key":"591_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40259-016-0175-4","volume":"30","author":"I Marcian\u00f2","year":"2016","unstructured":"Marcian\u00f2 I, Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, et al. How did the introduction of biosimilar filgrastim influence the prescribing pattern of granulocyte colony-stimulating factors? Results from a multicentre, population-based study, from five Italian centres in the years 2009\u20132014. BioDrugs. 2016;30(4):295\u2013306.","journal-title":"BioDrugs."},{"key":"591_CR17","unstructured":"CittadinanzAttiva. Indagine civica sull\u2019esperienza dei medici in tema di aderenza alle terapie, con focus su farmaci biologici e biosimilari. 2017. http:\/\/www.cittadinanzattiva.it\/files\/rapporti\/salute\/indagine-aderenza-terapie-focus-farmaci-biologici-biosimilari.pdf. Accessed 5 Oct 2017."},{"key":"591_CR18","unstructured":"Italian Medicines Agency. Criteri per la classificazione dei farmaci innovativi e dei farmaci oncologici innovativi. 2017. http:\/\/www.agenziafarmaco.gov.it\/content\/criteri-la-classificazione-dei-farmaci-innovativi-e-dei-farmaci-oncologici-innovativi-050420. Accessed 5 Oct 2017."},{"key":"591_CR19","unstructured":"Italian Medicines Agency. Registri Farmaci sottoposti a monitoraggio. http:\/\/www.agenziafarmaco.gov.it\/content\/registri-farmaci-sottoposti-monitoraggio. Accessed 5 Oct 2017."},{"issue":"5","key":"591_CR20","doi-asserted-by":"publisher","first-page":"e0155805","DOI":"10.1371\/journal.pone.0155805","volume":"11","author":"Y Ingrasciotta","year":"2016","unstructured":"Ingrasciotta Y, Giorgianni F, Marcian\u00f2 I, Bolcato J, Pirolo R, Chinellato A, et al. Comparative effectiveness of biosimilar, reference product and other erythropoiesis-stimulating agents (ESAs) still covered by patent in chronic kidney disease and cancer patients: an Italian population-based study. Mantovani LG, editor. PLoS One. 2016;11(5):e0155805.","journal-title":"PLoS One."}],"updated-by":[{"DOI":"10.1007\/s40261-017-0613-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T00:00:00Z","timestamp":1514592000000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-017-0591-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0591-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0591-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T09:22:57Z","timestamp":1651051377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-017-0591-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["591"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0591-3","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]},"assertion":[{"value":"26 October 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2017","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Unfortunately, many errors were identified in the published article. The original article was corrected.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Gianluca Trifir\u00f2 coordinates a research team at the University of Messina, which receives research grants for projects that are not related to the topic of the paper. Simona Lucchesi, Ilaria Marcian\u00f2, Paolo Panagia, Rosanna Intelisano, Maria Pia Randazzo, Carmela Sgroi, Giuseppe Altavilla, Mariacarmela Santarpia, Vincenzo Adamo, Tindara Franchina, Francesco Ferra\u00f9, and Paolina Reitano declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in the context of the \u201cProgetto Osservazionale sulla Psoriasi-SOPso\u201d, and received unconditional funding from Novartis, which did not interfere in any stage of the study. The financial assistance was used to access and analyze data from different centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All procedures performed in this study were in accordance with the Ethical Standards of the Institutional Research Committee of the Academic Hospital of Messina (minutes n.9\/2014, 21 July 2014), according to the current national law (8), and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The manuscript does not contain clinical studies and all patients\u2019 data were fully anonymized. For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}